drugset / Trial / NCT04588129
Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers
Phase 1
Completed
16 enrolled
LB Pharmaceuticals Inc.
Washington University School of Medicine · collab
RandomizedSingle-groupOpen-labelBasic science
Summary
This is an open label study in 4 cohort of 4 healthy volunteers each designed to evaluate the dopamine receptor occupancy of LB-102 at various doses and timepoints.
Timeline
- Start
- 2021-01-05
- Primary completion
- 2021-09-17
- Completion
- 2021-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LB-102 | Small molecule | 50 mg | Oral |
| Subject | LB-102 | Small molecule | 75 mg | Oral |
| Subject | LB-102 | Small molecule | 100 mg | Oral |